• Explore /
  • Poster
  • / Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).

Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).

Abstract Poster

Authors

null

Georg A. Bjarnason

Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

Georg A. Bjarnason , Jennifer J. Knox , Christian K. Kollmannsberger , Denis Soulieres , D. Scott Ernst , Christina M. Canil , Eric Winquist , Pawel Zalewski , Sebastien J. Hotte , Scott A. North , Daniel Yick Chin Heng , Robyn Jane Macfarlane , Peter M. Venner , Ian Tannock , Anil Kapoor , Bernhard J. Eigl , Aaron Richard Hansen , Piotr Czaykowski , Ben Boyd , Naveen S. Basappa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT01499121

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4555)

DOI

10.1200/jco.2015.33.15_suppl.4555

Abstract #

4555

Poster Bd #

229

Abstract Disclosures

Similar Posters

Poster

2017 ASCO Annual Meeting

Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.

Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.

First Author: Georg A. Bjarnason

First Author: Kathleen Margaret Mahoney

First Author: Ana-Alicia Beltran-Bless

First Author: Antoine Thiery-Vuillemin